These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10684707)

  • 21. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas.
    Haier J; Owzcareck M; Guller U; Spagnoli GC; Bürger H; Senninger N; Kocher T
    Anticancer Res; 2006; 26(3B):2281-7. PubMed ID: 16821603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum endostatin levels in patients with epithelial ovarian cancer.
    Hata K; Dhar DK; Kanasaki H; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Nagasue N; Miyazaki K
    Anticancer Res; 2003; 23(2C):1907-12. PubMed ID: 12820477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Significance of concentration of serum soluble vascular cell adhesion molecule-1 in epithelial ovarian carcinoma].
    Qiao XM; Wang ZM
    Ai Zheng; 2004 Jan; 23(1):81-4. PubMed ID: 14720381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer.
    Woong-Shick A; Sung-Pil P; Su-Mi B; Joon-Mo L; Sung-Eun N; Gye-Hyun N; Young-Lae C; Ho-Sun C; Heung-Jae J; Chong-Kook K; Young-Wan K; Byoung-Don H; Hyun-Sun J
    Cancer Sci; 2005 Mar; 96(3):197-201. PubMed ID: 15771624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.
    Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
    Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
    Hefler LA; Zeillinger R; Grimm C; Sood AK; Cheng WF; Gadducci A; Tempfer CB; Reinthaller A
    Gynecol Oncol; 2006 Nov; 103(2):512-7. PubMed ID: 16750560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation of glutathione S-transferase and its Pi isoenzyme in tumor tissues and sera of patients with ovarian cancer.
    Ghalia AA; Rabboh NA; el Shalakani A; Seada L; Khalifa A
    Anticancer Res; 2000; 20(2B):1229-35. PubMed ID: 10810426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
    Wang Q; Zhang W; Li DR; Li L
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
    Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
    Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer.
    Nishikawa H; Ozaki Y; Nakanishi T; Blomgren K; Tada T; Arakawa A; Suzumori K
    Gynecol Oncol; 2004 Mar; 92(3):881-6. PubMed ID: 14984956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
    Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
    Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.